The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid increased competition.
An article from
Dive Brief
The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid increased competition.
Published May 21, 2026
By
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
BioMarin to seek further approval of Voxzogo in form of short stature
UCB digs deeper into Bimzelx’s psoriatic arthritis win over Skyrizi
New data show VEGF bispecifics could compete with Summit, Akeso drug
Immunovant shares surge on arthritis trial data
EU and US advisers split over AstraZeneca breast cancer drug
A new ranking of pharma companies by R&D performance
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
BioMarin Pharmaceutical will seek expanded approval for its bone growth-stimulating drug Voxzogo after the shot improved growth…
Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring…
Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded…
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close…
Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
